A breakthrough DNA test, called Prosigna, has the potential to spare millions of breast cancer patients from chemotherapy. The test accurately identifies patients who can safely avoid this harsh treatment. This development means over two-thirds of women in a significant trial could skip chemotherapy.
The Prosigna test measures the activity of 50 genes linked to breast cancer growth. It calculates a patient's risk of the disease returning. Patients scoring low on the test did not receive chemotherapy. They still had high survival rates. Two-thirds of trial participants received low scores. Their five-year survival rate was 93.7%. Patients receiving chemotherapy had a survival rate of 94.9%.
This advancement fits into a broader effort for personalized medicine in cancer care. Traditionally, chemotherapy is often given after surgery to reduce recurrence risk for early-stage breast cancer. However, oncologists have worried about its limited benefit for certain common types. This study, involving over 4,000 patients in six countries, validates the use of tumour biology to guide treatment decisions. This contrasts with relying only on traditional clinical factors. The findings are expected to be presented at a major cancer conference in Chicago. This approach offers a more efficient use of healthcare resources.
Professor Rob Stein, the trial's lead investigator from University College London, highlighted the significance. "These results mark an important and significant step toward more personalised treatment," he stated. He added that the trial successfully used tumour biology to guide decisions. This move helps patients avoid chemotherapy's physical and emotional burdens. It also promises a more evidence-based use of health system resources.
The implications are substantial for patient well-being and healthcare systems. Millions globally could avoid severe side effects like fatigue, nausea, and hair loss. The study does not yet apply to patients under 40. Further results for this age group are still years away. Health systems may see reduced costs associated with chemotherapy. This new testing method represents a shift towards precision medicine in oncology.